[{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"daae1f05-12fe-4996-9dec-954e69831dae","acronym":"ICEMELT","url":"https://clinicaltrials.gov/study/NCT04631731","created_at":"2021-11-03T15:53:06.279Z","updated_at":"2025-02-25T14:29:43.930Z","phase":"Phase 1/2","brief_title":"Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity","source_id_and_acronym":"NCT04631731 - ICEMELT","lead_sponsor":"Western Sydney Local Health District","biomarkers":" LAG3 • HAVCR2","pipe":" | ","alterations":" HAVCR2 expression","tags":["LAG3 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HAVCR2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/10/2024","primary_completion_date":" 12/10/2024","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2023-06-01"},{"id":"53d79e9d-a4a5-4744-ac61-e6efb07bd6bc","acronym":"MIMOSA","url":"https://clinicaltrials.gov/study/NCT04368468","created_at":"2021-01-18T21:06:05.068Z","updated_at":"2024-07-02T16:35:58.565Z","phase":"","brief_title":"Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC","source_id_and_acronym":"NCT04368468 - MIMOSA","lead_sponsor":"Institut Claudius Regaud","biomarkers":" PD-L1 • LAG3 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • LAG3 expression • HAVCR2 expression","tags":["PD-L1 • LAG3 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • LAG3 expression • HAVCR2 expression"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 01/31/2021","study_completion_date":" 01/31/2021","last_update_posted":"2022-12-23"},{"id":"48e9888e-1610-4808-9875-839623d633eb","acronym":"CP-COPD","url":"https://clinicaltrials.gov/study/NCT04654104","created_at":"2021-01-19T20:41:13.728Z","updated_at":"2024-07-02T16:36:00.909Z","phase":"","brief_title":"Immune Checkpoints in COPD","source_id_and_acronym":"NCT04654104 - CP-COPD","lead_sponsor":"University of Catanzaro","biomarkers":" PD-L1 • PD-1 • CTLA4 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression","tags":["PD-L1 • PD-1 • CTLA4 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 12/10/2023","study_completion_date":" 12/10/2023","last_update_posted":"2022-11-07"},{"id":"a9a4b065-a72c-4e31-861d-bbef6a0e8d93","acronym":"PEOPLE","url":"https://clinicaltrials.gov/study/NCT03447678","created_at":"2021-01-18T16:59:58.507Z","updated_at":"2024-07-02T16:36:29.303Z","phase":"Phase 2","brief_title":"Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.","source_id_and_acronym":"NCT03447678 - PEOPLE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression","tags":["EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-06-09"},{"id":"b4c9f83c-8626-47ee-9e52-e028530c5264","acronym":"POIR","url":"https://clinicaltrials.gov/study/NCT03549546","created_at":"2021-01-18T17:28:29.609Z","updated_at":"2024-07-02T16:36:57.640Z","phase":"","brief_title":"Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.","source_id_and_acronym":"NCT03549546 - POIR","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" CD8 • PD-1 • CTLA4 • HAVCR2 • CD4 • IL2","pipe":" | ","alterations":" PD-1 expression • HAVCR2 expression • CTLA4 expression","tags":["CD8 • PD-1 • CTLA4 • HAVCR2 • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • HAVCR2 expression • CTLA4 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 02/06/2019","primary_completion_date":" 02/06/2019","study_txt":" Completion: 02/12/2019","study_completion_date":" 02/12/2019","last_update_posted":"2019-07-26"},{"id":"6c9af530-8085-4f9d-9020-804ff7130403","acronym":"","url":"https://clinicaltrials.gov/study/NCT00942578","created_at":"2021-01-18T03:39:36.607Z","updated_at":"2024-07-02T16:37:06.275Z","phase":"Phase 2","brief_title":"A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT00942578","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • HAVCR2","pipe":" | ","alterations":" CD8 expression • HAVCR2 expression","tags":["CD8 • PD-1 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • HAVCR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • docetaxel • lenalidomide • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 07/16/2009","start_date":" 07/16/2009","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 07/31/2017","study_completion_date":" 07/31/2017","last_update_posted":"2018-10-11"}]